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1. Introduction
Role of renal artery embolization (RAE) in strategy of treatment of renal carcinoma (RC) has
a multiyear history in scientific literature and in personal experience. In view of personal ex‐
perience we have a strong feeling that RAE is beneficial both in operable and advanced RC,
partially because of longer survival and stimulation of certain immune reactions [1].
RAE was introduced to clinical practice in the 70's of last century. The pioneers who devel‐
oped the technique of surgery were Lalli et al, in 1973 while Almgard et al. presented their
own experience with the application of RAE in renal cancer in humans [2,3]. At that time
arteriography was the basic diagnostic methods and identification of renal tumors was
made during the embolization. Today, vascular embolization procedures are becoming
widely used in the treatment of persistent bleeding, vascular defects and cancer.
In urology RAE is well established in the treatment of bleeding observed after jatrogennie
complications of NSS (nephron sparing surgery), PCN (percutaneous nephrostomy), ESWL
(extracorporeal shock wave lithotripsy), PCNL (percutaneous nephrolithotrypsy), closing
arteriovenous fistulas and the need to rempve kidney in the case of severe nephrotic syn‐
drome or secondary arterial hypertension [4, 7, 22].
Basic form of treatment of locoregional RC is surgical resection of kidney containing the
tumor (optionally with adrenal gland and extraperitoneal lymph nodules).  Recently it  is
adviced to introduce new, less  invasive surgical  techniques (laparoscopy and use of  ro‐
bots),  as  well  as  NSS  (nephron  sparing  surgery).  These  techniques  are  used  mostly  in
less advanced RC (T1) [25, 28, 29, 30].
In the strategy of treatment of more advanced RC frequently there is adviced application of
RAE [2,3]. RAE is a procedure based on introduction, with use of an angiographic catheter,
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into blood vessel an obstruction material aimed to interrupt blood supply to an organ or to
its particular region. At present different coils, haemostatic spongues, cyanoacrylic glues
and alcohols are applied as materials for RAE [2, 11, 19]. This leads to acute necrosis of tis‐
sues where blood flow has been amputeed, which in turn results in development of acute
phase reaction in the organism.
RAE is applied in treatment of RC for about 40 years [3]. It may be evoked prior to surgery,
considered as a technique succouring the surgery, or used as palliative embolization in
large, inoperable RC, mostly with intensive bleedings and/or pains. RAE which preceedes
nephrectomy provides better conditions for the surgery and allows to shorten time of the
intervention [1,4]. There exist informations that RAE may lead to stabilization and/or regres‐
sion of distal metastases. These effects may be due to immunomodulating effects of RAE
suggested by some authors [1,5]. However, knowledge on influence of RAE on immune sta‐
tus and response of immunocompetent cells is still scarce and fragmentaric. Systematic stud‐
ies of this issue are needed.
In view of multiple limitations in efficacy and safety of RAE the present indications for ap‐
plication of this procedure include mostly [6, 7, 18]:
• Palliative RAE in advanced RC which results in relief of life-treatening haematuria and
lumbar pains;
• Embolization of  large,  highly  vascularized neoplasms prior  to  surgery  (effective  RAE
results  in  contraction  of  vascular  collaterals,  facilitates  dissection  of  the  tumour,  and
allows to change the sequence of affixing renal vascular pedicle, ie first artery and the
renal vein later);
• Embolization of highly vascularized RC metastases (e.g. vertebral metastases).
Opinions on the role of preoperative RAE in the management of patients with RC are con‐
troversial. Although a significant number of studies on RAE are reported in RC patients,
there is no consensus on the benefits and morbidity associated with the procedure [7, 22].
Moreover, many large studies on the use of RAE both prior to nephrectomy and in ad‐
vanced RC were conducted in the 1980s, before the development of improved techniques
and imaging. Most proponents of preoperative RAE report the facilitation of nephrectomy
through decreased operative blood loss, ease of dissection secondary to the development of
oedema in tissue planes, and decreased operative time [8,9]. For those patients with signifi‐
cant tumour thrombus there might be a beneficial effect of decreasing the size or extent of
tumour thrombus before surgery [10]. Interestingly, there might also be an advantage in the
form of immunomodulation, whereby RAE-induced tumour necrosis stimulates a tumour-
specific response from the immune system of the host [11-13].
Own experience [1] includes 474 patients with RC of which 118 had RAE before nephrec‐
tomy. It  was reported that RAE significantly prolonged survival  time in T2 and T3 RC.
Additionally,  it  was found preliminarly that  RAE exerted immunotropic  effects  and en‐
hanced immune status of the patients. This diminished risks of the surgery. Recently we‐
continued these  investigations  and performed series  of  studies  on  response  of  immune
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system in patients with RC undergoing RAE [14].  We analyzed 50 patients with RC ex‐
ceeding diameter of 7 cm (T≥2) and tested immune status of persons with less and more
advanced RC. 30 patients underwent palliative RAE and assessment of immune status at
different  times  after  embolization.  The  complex  assessment  of  immune  status  included
large battery of microculture tests of peripheral blood mononuclear cells (PBMC), estima‐
tion of levels of certain cytokines and cytometric measurement of lymphocyte subpopula‐
tions  in  peripheral  blood.  It  was  found  that  RAE  lowers  the  suppressive  action  of
neoplastic cells on the immune system, results in normalization of disordered proportion
of  lymphocyte  subpopulations  (CD4,  CD8)  and  enhances  the  antiinflamatory  response
(increases  levels  of  certain  cytokines-  IL-10  and  IL-1ra).  All  together,  the  result  reveal
stimulation of  certain  functions  of  immunocompetent  cells  isolated from blood of  RAE-
treated RC patients.  Clinical  relevance of  these findings and concluding whether  or  not
RAE improved immune status of patients needs further studies.
2. Techniques of renal artery embolization
The initial indications developed in the 1970s for RAE were limited to symptomatic haema‐
turia and palliation for metastatic renal cancer [2,3]. With technical advances and growing
experience the indications have broadened to include conditions such as vascular malforma‐
tions, medical renal disease, angiomyolipomas (AMLs), and preoperative infarction. The in‐
troduction of smaller delivery catheters and more precise embolic agents has drastically
improved the morbidity associated with this technique [4]. RAE has continued to gain popu‐
larity as a minimally invasive approach for various urological conditions.
The technique of embolising hypervascular renal carcinomas dates back to 1969 when first
reported by Lalli et al [2]. Since then, various techniques and embolic materials have been
described. RAE has been used pre-operatively to facilitate nephrectomy [8], or to stimulate a
possible systemic response in patients with metastases [5]. Renal embolisation has been es‐
tablished as a palliative treatment for unresectable renal carcinoma and in patients with less
advanced disease (stage I–III) who, for whatever reason, are unsuitable or unwilling to un‐
dergo surgery [18, 22, 24]. In this group of patients the technique reduces tumour bulk and
relieves local symptoms such as pain or intractable haematuria.
However, opinions on the role of preoperative RAE in the management of patients with
RC are controversial.  Although a significant  number of  studies  on RAE are reported in
these  patients,  there  is  no  consensus  on the  benefits  and morbidity  associated with  the
procedure [7-9].
Effective embolization induces acute ischemic necrosis zone to form infarct of the organ tis‐
sues, which results in the onset of symptoms called postembolization syndrome, which usu‐
ally occurs within the first few days after RAE [8]. Greater risk of developing the
postembolization syndrome occurs in patients with small tumors, developing peripherally,
when still remains a large part of the normal, not embolized part of the kidney [9]. The side
effects which occur after RAE include: pain in the lumbar region, nausea and vomiting, hy‐
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perthermia, and fluctuations of blood pressure. These symptoms are usually temporary and
transient, and their severity depends on the extent of ischemia in the kidney area. In a small
percentage RAE may also lead to serious complications that are associated primarily with
the movement (migration) or embolic material backflow [12, 22]. The consequence of this
may be embolization of contralateral artery, mesenteric arteries, arteries of the lower limbs,
and ischemic spinal cord injury. The risk of serious complications is low, if RAE is per‐
formed well and professionally. In our clinic material including hundreds of treatments was
observed and serious complications developed, except of various symptoms of postemboli‐
zation syndrome [1].
If there is a real benefit to be gained, most proponents of preoperative RAE cite the facilita‐
tion of nephrectomy through decreased operative blood loss, ease of dissection secondary to
the development of oedema in tissue planes, and decreased operative time [10, 11, 26]. For
those patients with significant tumour thrombus there might be a beneficial effect of de‐
creasing the size or extent of tumour thrombus before surgery [12]. Interestingly, there
might also be an advantage in the form of immunomodulation, whereby RAE-induced tu‐
mour necrosis stimulates a tumour-specific response [1,5,13]. It is likely that RAE is underu‐
tilized, perhaps because of a lack of prospective randomized studies demonstrating these
potential benefits.
In our Departament of Clinical Urology the treatment of REA is performed under local anes‐
thesia wit 1% xylocaine after puncturing the femoral artery under fluoroscopic control
[1,14]. Vascular catheter is inserted into the abdominal aorta (Seldinger method). Aorto‐
nephrography is performed as the first step of the procedure (Fig.1 - A). This is followed by
selective catheterisation of renal arteries and contrast agent (usually Omnipac) is applied us‐
ing an automatic syringe (Fig. 1 - B). Image of arterial and venous intermediate is obtained
with angiographic confirmation of following RC characteristics:
• Increased flow through the renal artery and the resulting expansion of the arteries,
• Presence of pathological vascularization in arterial phase (numerous, tortuous vessels
with impaired angioarchitectonics)
• Nephrograms with the image of tumorous discoloration occuring due to retention of con‐
trast in blood vessels,
• Loss of saturable renal parenchyma.
This  is  followed by injecting the  embolizing material  through a  vascular  catheter.  Most
frequently  used is  Spongostan which is  fragmented and placed at  the  end of  a  syringe
filled with 0.9% NaCl, and then injected into renal artery. Spongostan embolization often
supplemented with  different  coils.  In  case  of  confirmation in  renal  arteriography of  tu‐
mor vascularization by more  than one artery,  respectively  all  the  supplying vessels  are
embolized, as above.
The whole procedure of RAE (Fig. 1 A – D) lasts about 30 – 60 minutes and its effectiveness
(lack of blood flow in renal vessels) is confirmed in angiography after re-injection of contrast
medium through the catheter withdrawn to the aorta.
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Figure 1. Stages of vascular embolization of renal artery. A. arteriography; B. vascularization of renal tumour; C. mate‐
rial for embolization injected to renal artery; D. closed renal artery.
After completing the RAE procedure the femoral artery puncture site is deemed temporary
with pressure dressing. Few hours after RAE standard blood tests, monitoring of urine out‐
put and assessment of severity of postembolization symptoms (lumbar pain - a symptom
that occurs in nearly all patients after effective RAE, nausea, vomiting, fever, transient renal
failure and symptoms of gastrointestinal paralytic ileus). Medication (analgesic, antispas‐
modic, prokinetic agents, anticoagulants drugs and antibiotics) are prescribed appropriately
to symptoms and depending on the clinical situation. In the study group of 474 patients
there were no clinically significant complications (death, femoral hematoma, migration of
embolizing material or ischemic spinal cord injury) [1,14].
Time schedules of RAE and nephrectomy are not established precisely, usually RAE is made
few – several days before nephrectomy. In some cases RAE is made one only day before sur‐
gery to avoid acute postembolization syndrome.
3. Survival of renal cancer patients treated with renal artery embolization
Up to 30% of patients diagnosed with RC have metastatic disease at presentation [27]. De‐
spite its sometimes favourable course, patients with metastatic RC generally die within 2
years of diagnosis. DeKernion et al [20] found that cumulative survival in 86 patients with
metastatic RCC was 53% at 6 months, 43% at 1 year, 26% at 2 years and 13% at 5 years. The
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treatment of patients with metastatic RC has not improved over the years and continues to
pose a problem for clinicians. Surgery is not curative in this group; however, recent advan‐
ces in immunotherapy have rekindled interest in cytoreductive nephrectomy. A combined
analysis [21] of two prospective randomized trials, [15, 16], found a small survival advant‐
age (5.8 months) in patients who underwent nephrectomy followed by interferon-alpha
based immunotherapy compared with immunotherapy alone. This survival benefit relates
to patients with a good performance status whose primary tumour has been assessed to be
surgically operable and who are good candidates for subsequent immunotherapy. Unfortu‐
nately, many elderly patients with disseminated RC do not fit these criteria and have signifi‐
cant comorbidity. Radical nephrectomy may cause significant morbidity post-surgery,
particularly in elderly patients, and in some cases precludes the use of systemic therapy. It is
in this situation that renal artery embolisation appears to have a role.
Previous studies had reported that delayed nephrectomy following embolisation of RC may
be of clinical benefit to high risk patients with reduction in the size and vascularity of the
primary tumour prior to surgery [9]. Subsequent studies have, however, found no survival
benefit for patients with metastatic disease undergoing embolisation and nephrectomy [23].
The survey also indicated that a significant proportion of respondents (35%) still believed
that the technique had a role in palliation of haematuria or pain in unfit or inoperable cases,
or as the sole treatment modality in patients with metastatic disease.
Park et al [19] investigated the effectiveness of RAE with a mixture of ethanol and lipiodol
in 27 patients with unresectable RC. 10 of the patients had stage III disease with 15 of the 27
patients having stage IV disease. Overall the median survival of the 27 patients was 8.5
months. The median survival was 23 months in the 10 patients with stage III disease and 7
months in 15 patients with stage IV disease. A similar study by Onishi et al [24] compared
two groups of patients with unresectable RC with stage IV disease. 24 patients underwent
renal embolisation with ethanol while 30 patients did not have any intervention. The me‐
dian survival for the renal embolisation group was 229 days and for the control group 116
days. Those undergoing renal embolisation had a significantly better prognosis than those
who did not (p=0.019). Other authors [18, 25, 26] have reported median survival times for
patients treated with renal embolisation ranging from 4 months to 8.4 months. This equates
to a 1 year survival rate of 36.8% and a 2 year survival rate of 15.8%. Ridley et al. [28] sup‐
port the view that embolisation is not a curative treatment and probably only minimally al‐
ters the natural course of the disease, but it gives palliation of local symptoms related to
advanced renal malignancy and is a safe alternative to radical nephrectomy, with low mor‐
bidity and complication rate and shorter hospital stay.
In own studies [1] a series of 474 patients with RC, who had radical nephrectomy during a peri‐
od of 15 years, was studied to assess the prognostic significance of various pathologic parame‐
ters (tumor stage [pT], lymph node status, metastasis, tumor grade, venous involvement) and
value of preoperative RAE. There were: 20 (4%) pT1, 204 (43%) pT2, 245 (52%) pT3, and 5 (1%)
pT4 patients. All 474 patients underwent nephrectomy including a group of 118 (25%) patients
(24 pT2, 90 pT3, and 4 pT4) who underwent preoperative embolization of the renal artery. To
compare treatment outcomes in embolized patients with RC, a group of 116 (24%) nonembol‐
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ized patients with RC was selected. This group was matched for sex, age, stage, tumor size, and
tumor grade, with the embolized patients (p < 0.01). All important prognostic factors were
studied as to their influence on survival by the treatment group. The overall 5- and 10-year sur‐
vival was 62% and 47%, respectively (Figure 2). The 5- and 10-year survival rates were signifi‐
cantly better (p < 0.01) for patients with pT2 than for those with pT3 tumors (79% vs. 50% and
59% vs. 35%, respectively) (Figure 2). Involvement of regional lymph nodes (N+) was an impor‐
tant prognostic factor for survival in patients with pT3 tumors. The 5-year survival for pT3 N+
was 39%, compared with 66% in those with pT3N0 (p < 0.01). Preoperative embolization was
also an important factor influencing survival (Figure 3).
Figure 2. Estimated probability of survival from all causes of death by pathologic stage, pT2 vs. pT3. Open circles rep‐
resent death of a patient. Tick marks represent a patient who was alive at last follow-up.
Figure 3. Estimated probability of survival in the 118 patients treated with preoperative embolization as compared to
the 116 patients in radical nephrectomy alone group (matched patients).
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The overall 5- and 10-year survival for 118 patients embolized before nephrectomy was 62%
and 47%, respectively, and it was 35% and 23%, respectively, for the matched group of 116 pa‐
tients treated with surgery alone (p = 0.01). The most important finding of this study was an ap‐
parent importance of preoperative embolization in improving patients' survival. This finding
needs to be interpreted with caution and confirmed in a prospective randomized trial.
In conclusion, the available data suggest that RAE is a convenient, relatively tolerable man‐
agement option in patients with unresectable renal tumours and in patients unfit or unwill‐
ing to undergo surgery as a means of palliation of local symptoms and improving clinical
status. We believe there is also a role for this procedure in asymptomatic patients who have
potentially resectable disease who are unfit or unwilling to undergo surgery, and in asymp‐
tomatic patients with inoperable metastatic disease.
4. Reaction of immune system to renal artery embolization
RC, with the tumor growth, and then the spread of tumor tissue beyond the original lo‐
cation, begins to affect the activity of the immune system [14].  Nakano et al [5] indicate
the  importance  of  cell  proliferation  inhibitory  factor  present  in  the  serum  of  patients
with  RC.  Lymphocytes  in  RC  patients  without  any  therapy,  stimulated  in  vitro  with
PHA (phytohemagglutinin) in the presence of own serum responded very weakly to this
mitogen.  After  RAE  the  impact  of  this  inhibiting  factor  enhanced  and  proliferation  of
PHA-stimulated  lymphocyte  was  still  lowered [5].  Nephrectomy in  patients  not  treated
with RAE before surgery did not influence the ability of cells to stimulation by PHA. In
contrary,  patients who had RAE prior to nephrectomy the proliferation inhibitory factor
quickly disappeared and proliferative response to PHA was normal already 2 months af‐
ter surgery [5]. Catalona et al [34] reported that cell response to Con A (concanavalin A)
is impaired in case of urological cancers, including RC, and the cells have a high immu‐
no-suppressor  activity.  The  abolition  of  the  high  suppressor  activity  may  be  necessary
for effective treatment of RC [34]. Osada et al [35] in their study of 50 patients with RC
confirmed a  significant  increase  of  helper  and cytotoxic  NK lymphocytes  10-12  months
after  RAE.  This  was  very  impressive,  when  compared  to  lowered  values  of  these  cells
prior  to  RAE,  suggesting  that  RAE  enhanced  the  immune  status  [35].  Similar  results
were obtained by Bakke et al [13], who conducted a study of NK cell activity in patients
with RC after RAE. Blood samples of 30 patients were taken before RAE and 24, 48,  72
and 96  hours  after  surgery.  Surgery  was  performed to  remove  the  kidney  from 5  to  7
days after RAE. RAE resulted in increase in NK cells, with peak values observed after 48
hours  [13].  RAE in  patients  with  RC is  performed in  presence  of  potential  existence  of
immune deficiency caused by cancer itself. Therefore, in this case, the immune responses
(still  poorly  understood and inconsistent)  observed at  different  times after  embolization
(usually few-several days after RAE) will be the result of the two, often different operat‐
ing  mechanisms:  1.  response  to  ischemia  and  tissue  necrosis  and  inflammation  in  the
area  of  embolization  of  a  probable  stimulation  of  the  macrophage-monocyte  system;  2.
release from tumor tissues of various factors affecting the immune system, at least some
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of  which  appear  to  have  an  immunosuppressive  effect.  The  main  task  of  the  immune
system is  to  maintain  homeostasis.  The  basic  unit,  often  defined  as  "immune  orchestra
conductor" is thymus-dependent T lymphocyte,  which, based on the phenomenon of re‐
striction major histocompatibility complex I and II expresses the phenomenon of violence
against  its  own unnormal or  changed antigens,  and the phenomenon of  tolerance to its
own antigens  [32,  33].  Embolization  may  lead  to  stimulation  of  the  immune  system in
the  following  mechanism:  close  off  blood  supply  to  the  tumor  leads  to  necrosis  which
gives a chance to enhance antigenicity of cancer cells and evoke the potential amplifica‐
tion of the immune system [14]. This leads in turn to destruction of tumor tissue by infil‐
tration with cytolytic immunocompetent cells.
Recent studies in patients with metastatic RC have shown a small survival advantage in pa‐
tients undergoing radical nephrectomy followed by immunotherapy; however, these studies
are biased towards patients with good performance status aqccording to ECOG (Eastern Co‐
operative Oncology Group) scale status 0 or status 1. This small survival benefit should also
be viewed in light of the morbidity and mortality associated with a large surgical procedure.
The increased morbidity associated with radical nephrectomy may preclude or delay the ad‐
ministration of systemic immunotherapy, which has demonstrated reproducible response
rates of 10–20% [15].
In two randomized trials with identical design, patients who underwent nephrectomy fol‐
lowed by interferon alpha (IFN-α) therapy had improved survival (median 13.6 months)
compared with those treated with IFN-α alone (median 7.8 months) [15, 16]. The antivascu‐
lar endothelial growth factor (VEGF) antibody; the multityrosine kinase inhibitors, sorafe‐
nib, sunitinib, and pazopanib; and the mammalian target of rapamycin (mTOR) inhibitors,
temsirolimus and everolimus, have become the mainstay of therapy for the vast majority of
patients with metastatic renal cell carcinoma (mRCC). Large randomized controlled clinical
trials have shown improved progression-free survival with these agents and improved sur‐
vival in selected populations, but the majority of these study patients had prior nephrecto‐
my and good performance status [16, 17, 20, 21].
In  own  studies  [14]  we  examined  functional  status  of  immunocompetent  cells  isolated
from peripheral  blood of  patients  with  advanced RC treated  with  RAE.  Blood samples
were  collected  by  vein  puncture  and  peripheral  blood  mononuclear  cells  (PBMC)  were
isolated on Ficol-Paque gradient, and after determination of cell viability (usually no less
than 80% viable cells), the microcultures were set up in triplicates (105  cells/0.2 ml RPMI
+ 15% autologous inactivated serum) in Nuncoln microplates. Respective triplicates were
left without stimulation or stimulated with phytohemagglutinin (PHA, HA16, Murex Bio‐
tech Ltd Dartford U.K.,  0.4 μg/cult.)  or with concanavalin A (Con A, Sigma, 8 μg/cult.).
The  plates  were  placed  inside  the  anechoic  chamber  in  the  ASSAB  incubator  at  37o  C
and 5% CO2. An identical plate of control cultures was also set up and placed in the AS‐
SAB incubator beyond the chamber. At 24h of incubation, rearrangements of the cultures
were performed as described elsewhere [32,33].
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As a result of rearrangements of cultures performed at 24 h, the following parameters of
T cell  and monocyte  activities  were  measured at  the  end of  cultures:  T  lymphocyte  re‐
sponse  to  PHA  and  to  Con  A,  saturation  of  IL-2  receptors,  T  cell  suppressive  activity
(SAT index),  and the index of monocyte immunogenic activity (LM) related to the ratio
of produced monokines (IL-1β versus IL-1ra) [32]. For the last 18h of incubation, 3H-thy‐
midine  (3HTdR,  Amersham,  U.K.,  spec  act.  5Ci/mM)  was  added  into  the  cultures  in  a
dose of 0.4 μCi/cult.
At 72h the cultures were harvested and incorporation of 3HTdR was measured in Pack‐
ard Tri carb 2100 TR scintillation counter. The results were calculated as a mean value of
dpm (desintegrations per  minute)  per  triplicate  of  cultures  ±  SD.  The experiments  were
repeated 10 times, and the results observed in the exposed cultures were compared with
those  obtained  in  the  control  cultures.  The  data  were  analyzed  with  STATGRAPHICS
PLUS  6.0  version.  The  differences  between  the  mean  values  were  assumed  statistically
significant if  the p values, calculated withthe use of U Mann-Whitney’s test,  were lower
than 0.05.
The  results  obtained  in  this  study  are  summarized  in  Table  1  and  described  in  detail
elsewhere [14].
In the analysis of  50 patients with RC treated with RAE, we selected 30 patients where
RAE was the only form of treatment. In this group of patients the immune response was
studied at  different  times  after  the  palliative  RAE (output  test,  the  test  after  2-6  weeks
and at 12 weeks after RAE) successive assessment of significant differences in the magni‐
tude and direction of  change of  parameters  characterizing the efficiency of  the immune
system. It was found that RAE performed in patients with advanced RC exerts immuno‐
modulatory  effect  on the  immune response  manifested by the  increase  of  the  prolifera‐
tive response to PHA and the percentage of  CD4 + cells,  and significant increase in the
value of saturation of the receptors, IL-2, a cytokine with protrophic properties (Table 1).
After RAE significant increase was observed in inflammatory response manifested by the
increase of  T regulatory cells,  which can be a potential  source of  IL-10,  cytokine inhibi‐
tion of the function of the inflammatory response (Table 1).
It was found that RAE lowers the suppressive action of neoplastic cells on the immune sys‐
tem, results in normalization of disordered proportion of lymphocyte subpopulations (CD4,
CD8) and enhances the antiinflamatory response (increases levels of certain cytokines- IL-10
and IL-1ra). All together, the result reveal stimulation of certain functions of immunocompe‐
tent cells isolated from blood of RAE-treated RC patients. Clinical relevance of these find‐
ings and concluding whether or not RAE improved immune status of patients needs further
studies [1, 14].
The changes in the immune system may, however be heterogeneous and multidirectional
and individually changebale. This would indicate that the systemic inflammatory response
is not only associated with the release of cytokines from a kidney tumor, and it rather results
from the defective immune response in patients with advanced cancer [14].
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Investigated parameter RAE-treated RC patients (T 3 and 4)N=30
PHA Lowering after 2-6 weeks *Increase after 12 weeks
ConA Lowering after 2-6 weeks *Lowering after 12 weeks
IL-2 Lowering after 2-6 weeksIncrease after 12 weeks
LM No significant differences after 2-6 weeksLowering after 12 weeks
SAT Increase after 2-6 weeksNo significant differences after 12 weeks
CD3+ Increase after 2-6 weksNo significant differences after 12 weeks
CD4+ Increase after 2-6 weeksIncrease after 12 weeks
CD8+ Lowering after 2-6 weeks *Lowering after 12 weeks
CD4+/CD25high Increase after 2-6 weeksIncrease after 12 weeks
NK No significant differences after 2-6 weeksNo significant differences after 12 weeks
IL-1β Increase after 2-6 weeksLowering after 12 weeks
IL-6 Increase after 2-6 weeksLowering after 12 weeks
TGF-β Lowering after 2-6 weeks *Increase after 12 weeks
IL-1ra Lowering after 2-6 weeks *Increase after 12 weeks
IL-10 Lowering after 2-6 weeks *Increase after 12 weeks
Table 1. Summary of changes in investigated functional parameters of immune system in a group of 30 patients with
advanced RC treated with RAE (p<0.05).
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5. Summary and conclusions
In summary, the present authors conclude that patients with advanced RC benefit from RAE
with longer survival. RAE applied prior to nephrectomy facilitates surgery and additionally
prolongs survival. Additionally, RAE appears to be a potent immunostimulatory agent. It is
our strong feeling that in specialistic urologic centers RAE is a safe procedure which suc‐
cours the complex therapeutic process in patients with RC.
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